Anti-Galectin-1 Monoclonal Antibody

Galectin-1 (Gal-1) is a ubiquitously expressed galactoside-binding 14-kDa lectin that is differentially expressed by a variety of pathological as well as normal cell types. Extracellular Gal-1 has been shown to exert strong Immunomodulatory activity and has been implicated in numerous cancer and autoimmune diseases. Further, recent research has shown Gal-1 expression to influence tumor progression and invasion. Because of this, Gal-1 is a protein of significant interest and novel approaches to inhibiting its function are being investigated.

 

Researchers at Arizona State University and collaborators have generated a non-neutralizing, non-blocking, Anti-Gal-1 monoclonal antibody (mAb) using classical hybridoma techniques. This mAb binds to cell surface Gal-1, as well as intracellular Gal-1 and does not cross-react with other galectins. When evaluated on other Treg-like cell lines, this mAb detected intracellular Gal-1 in Tregs, MoT, MT-2 and MT-266, but not H9 cells. When binding was evaluated to MDA-MB-231 and MCF7 (highly aggressive and non-metastatic breast cancer cell lines, respectively), this mAb was able to detect higher levels of intracellular Gal-1 in MDA-MB-231 compared to MCF7. This mAb is compatible with flow cytometry and intracellular staining and as such may be used to further the study of Gal-1 protein expression and function.

 

This mAb provides a new tool which may be useful in research and or diagnostic settings for the study of Gal-1-T cell interactions, function and immunosuppression.

 

Potential Applications

Benefits and Advantages

 

For more information about this opportunity, please see

For more information about the inventor(s) and their research, please see